🔗 Permalink

Inventor profile of:

David Satijn

City:

Utrecht

Country:

Netherlands

Published Applications:

Last publication date:

2026-06-04

Top Assignees for applications by David Satijn

The entities that hold a legal rights for patent applications filed by inventor Satijn David:

GENMAB A/S 14 Copenhagen V, Denmark
BioNTech SE 13 Mainz, Germany
H. LUNDBECK A/S 11 Valby, Denmark
GENMAB A/S 8 Valby, Denmark
GENMAB A/S 6 Copenhagen, Denmark
Ganmab A/S 1 Valby, Denmark
GENMAB A/S 1 Copenhagen, Germany

Recent patent applications by Satijn David

David Satijn from Utrecht, NL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-06-04

US20260151500A1

Human necessities

ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER

#2 | 2026-03-26

US20260085126A1

Chemistry; metallurgy

AGONISTIC TNF RECEPTOR BINDING AGENTS

#3 | 2025-10-30

US20250333527A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

#4 | 2025-10-30

US20250333526A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

#5 | 2025-10-23

US20250325643A1

Human necessities

BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY

#6 | 2025-09-18

US20250289900A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#7 | 2025-09-18

US20250289899A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#8 | 2024-12-05

US20240400703A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

#9 | 2024-11-28

US20240392032A1

Chemistry; metallurgy

ANTIBODIES

#10 | 2024-11-14

US20240376221A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

#11 | 2024-09-26

US20240317861A1

Chemistry; metallurgy

ANTIBODIES AGAINST PD-L1

#12 | 2024-09-05

US20240294661A1

Chemistry; metallurgy

HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR

#13 | 2024-08-01

US20240254252A1

Chemistry; metallurgy

TROGOCYTOSIS-MEDIATED THERAPY USING CD38 ANTIBODIES

#14 | 2024-08-01

US20240254249A1

Chemistry; metallurgy

AGONISTIC TNF RECEPTOR BINDING AGENTS

#15 | 2024-07-11

US20240228641A9

Chemistry; metallurgy

ANTIBODIES BINDING TO CD30 AND CD3

#16 | 2024-04-25

US20240132607A1

Chemistry; metallurgy

ANTIBODIES BINDING TO CD30 AND CD3

#17 | 2024-03-21

US20240091352A1

Human necessities

ANTIBODIES BINDING AXL

#18 | 2023-11-16

US20230365714A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO ROR2 AND BISPECIFIC ANTIBODIES BINDING TO ROR2 AND CD3

#19 | 2023-10-12

US20230321261A1

Human necessities

AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT

#20 | 2023-10-05

US20230312693A1

Chemistry; metallurgy

Agents, Uses and Methods for the Treatment of Synucleinopathy

#21 | 2023-07-06

US20230212301A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#22 | 2023-04-27

US20230132049A1

Chemistry; metallurgy

Antibodies binding to CD30 and CD3

#23 | 2023-04-06

US20230109496A1

Chemistry; metallurgy

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#24 | 2023-03-23

US20230089969A1

Chemistry; metallurgy

MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137

#25 | 2023-03-23

US20230087745A1

Chemistry; metallurgy

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

#26 | 2023-03-09

US20230076417A1

Chemistry; metallurgy

MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS

#27 | 2022-12-29

US20220411522A1

Chemistry; metallurgy

ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

#28 | 2022-06-02

US20220169738A1

Chemistry; metallurgy

MONOCLONAL ANTIBODIES AGAINST HER2

#29 | 2022-03-03

US20220064317A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#30 | 2022-02-17

US20220049013A1

Chemistry; metallurgy

Antibodies

#31 | 2022-02-03

US20220033510A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#32 | 2021-12-02

US20210369842A1

Human necessities

ANTIBODY FORMULATION

#33 | 2021-10-14

US20210317225A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#34 | 2021-09-09

US20210277133A1

Chemistry; metallurgy

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

#35 | 2021-09-02

US20210269541A1

Chemistry; metallurgy

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

#36 | 2021-08-19

US20210253725A1

Chemistry; metallurgy

Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)

#37 | 2021-07-29

US20210230296A1

Chemistry; metallurgy

Antibodies

#38 | 2021-06-03

US20210163616A1

Chemistry; metallurgy

Binding agents binding to PD-L1 and CD137 and use thereof

#39 | 2021-05-20

US20210147522A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#40 | 2021-04-29

US20210122830A1

Chemistry; metallurgy

MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE

#41 | 2021-03-11

US20210070877A1

Chemistry; metallurgy

Antibodies

#42 | 2021-03-04

US20210061892A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#43 | 2021-02-25

US20210054057A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#44 | 2021-02-04

US20210030888A1

Human necessities

ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER

#45 | 2020-12-24

US20200397913A1

Human necessities

AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT

#46 | 2020-09-03

US20200277397A1

Chemistry; metallurgy

ANTIBODIES

#47 | 2020-08-06

US20200247899A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#48 | 2020-07-30

US20200239579A1

Chemistry; metallurgy

ANTIBODIES AGAINST PD-L1

#49 | 2020-06-25

US20200199231A1

Chemistry; metallurgy

BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20

#50 | 2020-06-04

US20200171152A1

Human necessities

ANTIBODIES BINDING AXL

#51 | 2020-05-28

US20200165349A1

Chemistry; metallurgy

Binding agents binding to PD-L1 and CD137 and use thereof

#52 | 2020-03-12

US20200079866A1

Chemistry; metallurgy

Agonistic tumor necrosis factor (TNF) receptor binding agents

#53 | 2020-02-27

US20200062853A1

Chemistry; metallurgy

Methods of producing multispecific antibodies against CD40 and CD137

#54 | 2019-12-19

US20190382473A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#55 | 2019-12-05

US20190367595A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#56 | 2019-12-05

US20190367594A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#57 | 2019-11-21

US20190352423A1

Chemistry; metallurgy

MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS

#58 | 2019-10-17

US20190315880A1

Chemistry; metallurgy

HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR

#59 | 2019-09-12

US20190275149A1

Human necessities

Antibodies binding AXL

#60 | 2019-07-04

US20190202926A1

Chemistry; metallurgy

ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

#61 | 2019-05-30

US20190160170A1

Human necessities

Antibodies binding AXL

#62 | 2019-01-24

US20190022243A1

Human necessities

AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT

#63 | 2018-11-15

US20180326084A1

Human necessities

AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT

#64 | 2018-08-02

US20180215827A1

Chemistry; metallurgy

Monoclonal antibodies against HER2

#65 | 2018-08-02

US20180214549A1

Human necessities

Antibodies binding AXL

#66 | 2018-07-12

US20180194849A1

Chemistry; metallurgy

Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains

#67 | 2018-07-12

US20180194845A1

Chemistry; metallurgy

Monoclonal antibodies against HER2

#68 | 2018-06-28

US20180179271A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#69 | 2018-06-28

US20180179270A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#70 | 2018-05-10

US20180127492A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#71 | 2018-05-10

US20180127491A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#72 | 2018-01-25

US20180022816A1

Chemistry; metallurgy

Monoclonal antibodies against HER2 epitope

#73 | 2017-12-14

US20170355767A1

Chemistry; metallurgy

Bispecific antibodies against CD3 and CD20

#74 | 2017-06-08

US20170157250A1

Human necessities

Antibodies binding AXL

#75 | 2017-05-18

US20170136130A1

Human necessities

HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR

#76 | 2017-01-19

US20170015739A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#77 | 2013-07-25

US20130189271A1

Chemistry; metallurgy

Monoclonal antibodies against HER2

#78 | 2013-07-04

US20130171148A1

Chemistry; metallurgy

Monoclonal antibodies against HER2 epitope

InventorID:

323303 ⎘